Background. Drug resistance development in the human immunodeficiency virus (HIV)-infected pediatric population in the United States can impact long-term antiretroviral therapy (ART) efficacy. Limited formularies and adherence constraints in children jeopardize lifelong-needed ART.
Highly active antiretroviral therapy (HAART) decreases morbidity and mortality of human immunodeficiency virus type 1 (HIV-1)-infected children [1] . However, medication effectiveness can be hindered by development of drug resistance (DR) [2] . Consequently, US pediatric treatment guidelines recommend DR testing prior to treatment initiation and before antiretroviral therapy (ART) regimen change [3] . Younger children are at high risk of DR development due to high viral loads (VLs) [4] , less robust immune responses [5] , and accurate dosing challenges owing to formulary limitations, potentially leading to subtherapeutic drug concentrations [6] . Further limitations to ART success include adherence challenges related to complex psychosocial factors, such as lack of caregiver support, denial of HIV diagnosis, and disclosure [7] .
The rate of new pediatric HIV infections in the United States is low (0.4 per 100 000 children aged <13 years) [8] ; however, DR development can be a major concern in the already infected population that needs lifelong ART. Published data on transmitted DR (TDR) in US children are limited to 3 studies in infants (12%-24% TDR between 1998 and 2005 [9] [10] [11] ) and 2 studies in adolescents (18% TDR in 2004 and 2014 [12, 13] ). Even fewer data are available on DR in ART-experienced US children, including 1 study reporting DR in 61% of 18 adolescents from Pediatric AIDS Clinical Trials Group 381 [14] ; 1 study on sexual risk behaviors of perinatally infected adolescents with DR in 81% of 37 youth [15] ; and 1 study with DR in 65% of 47 perinatally infected children [16] .
Sequences obtained for DR testing in routine care can be used for additional purposes such as subtype determination, which may impact DR development [17] and characterization of transmission networks. Despite reports of increasing HIV-1 diversity in US adults [18, 19] , >90% of HIV-infected individuals in North America harbor subtype B [20] . Subtype diversity reports in US children vary, with 3%-17% carrying non-B subtypes [10, 11, 16] , possibly due to geographic differences in immigration rates from higher-prevalence settings. Phylogenetic transmission networks analyses can provide information on common HIV sources (ie, mother-to-child transmission or sexual networks) [21] . Characterization of these networks is important for HIV transmission disruption; however, such analyses have been performed mostly in adults [22] .
We characterized treatment failure, DR, subtype diversity, and molecular epidemiology, and examined their correlates and potential impact on patient care, in the pediatric HIV clinic in Rhode Island.
METHODS

Study Design
The HIV clinic at Hasbro Children's Hospital is the sole pediatric HIV center in Rhode Island. A retrospective chart review was conducted for all HIV-1-infected children attending the clinic from 1991 through June 2012. Information collected included demographics (diagnosis age, birth country, refugee status, caregiver, transmission mode), clinical data (ART regimens, adherence, psychiatric history, opportunistic infections), and laboratory data (VL, CD4 cell count). Adherence was estimated by report of missed ART doses from child, caregiver or clinician; and history of missed appointments (defined as <3 per year). The Lifespan Institutional Review Board approved the study.
Sequence Analysis
Pol genotyping was performed as part of clinical care at Quest Diagnostics (Department of Molecular Diagnostics, Chantilly, Virginia), and FASTA sequences were obtained. Sequence quality control was performed with SQUAT [23] ; subtyping used REGA version 2.0 (http://www.bioafrica.net/index.php); and alignment was in MUSCLE (http://www.ebi.ac.uk/Tools/msa/ muscle), manually manipulated in BioEdit (http://www.mbio. ncsu.edu/bioedit/bioedit.html). Maximum likelihood trees were constructed in MEGA version 5.05 [24] using subtree pruning regrafting heuristics based on the GTR + G model of evolution with 4 discrete gamma categories with bootstrapping support (1000 replicates). DR positions were removed to minimize convergent evolution (ie, sequence similarity due to mutation patterns rather than viral ancestry). Transmission clusters were defined as sequences with 100% tree bootstrap support and short (<1.5%) genetic distances [25] .
DR interpretation was done with Stanford HIV Sequence Database tools (http://hivdb.stanford.edu) using the International Antiviral Society-USA (IAS-USA) DR mutation (DRM) list [26] for ART-experienced children, and the World Health Organization (WHO) surveillance DR mutation (SDRM) list [27] for ART-naive children. Cumulative DRMs were recorded when >1 sequence was available, and mutations were only counted once. Minor protease mutations were excluded from DR calculations due to their natural occurrence in non-B subtypes [17] .
Statistical Analysis
Due to the observational nature of this study and wide-ranging treatment histories, ART-experienced children were classified into 6 mutually exclusive treatment response categories: (1) suppressed: VL < 400 copies/mL at ≥12 months since treatment initiation; (2) probable response: VL ≥ 400 copies/mL at <12 months but at least 1-log-unit VL drop within 6 months; (3) possible failure: VL > 400 copies/mL at <12 months without a 1-log VL drop within 6 months; (4) failure after suppression: VL > 1000 copies/mL (accounting for intermittent episodes of low-level viremia [3] ) after previous VL suppression on ≥12 months of treatment; (5) failure with no suppression: VL > 400 copies/mL with no prior suppression after ≥12 months of treatment; and (6) suppression after previous failure: VL < 400 copies/mL for ≥12 months after previous failure. For analyses of correlates of failure, categories 1 and 2 were combined to a "suppressed" group, and categories 3-6 were combined to a "failure" group. The cutoff for virologic suppression was set at 400 copies/mL, the threshold for the earlier VL assays.
Due to limited sample size and many collected covariates, and to preserve type 1 statistical error, 7 covariates were selected for hypothesis testing of their association with virologic failure or presence of DRM: (1) primary caregiver change, (2) HIV disclosure to child, (3) denial of HIV diagnosis by child and/or caregiver, (4) history of missed appointments, (5) history of any missed doses, (6) history of psychiatric illness, and (7) infection with non-B subtypes. These covariates were selected because we hypothesized that they were associated with poor adherence or DR development. Associations between the selected covariates and virologic failure were evaluated using generalized additive models, which allowed for flexible adjustment for 3 potential confounders-age at first clinic visit, time on ART, and clinic enrollment prior to 1996 (before the HAART era). Associations between the covariates and DR were examined using Fisher exact test due to small sample sizes.
RESULTS
Study Cohort Characteristics
From 1991 to 2012, 56 HIV-1-infected children were seen at the clinic, 44 (79%) of whom were ART experienced at data collection (Table 1) . Charts were reviewed for all children. One-third of children were aged <1 year at diagnosis, 31% aged 1-4 years, and 37% aged ≥5 years. More than half (54%) were male and 73% were black/Hispanic. Fifty-five percent were born in the United States, 20% were refugees, and nearly two-thirds (64%) were perinatally infected. For 7 children, the mode of transmission was unknown; all were diagnosed in late childhood or adolescence, with mothers who either tested HIV negative (n = 1) or were unavailable for testing (n = 6). Two-thirds were enrolled in the clinic at data collection, the remaining having either transferred to the adult clinic or relocated. Compared to ART-experienced children, ART-naive children were older at diagnosis and less likely to be perinatally infected.
HIV Diversity and Molecular Epidemiology
Pol sequences were available for 40 of 56 children (71%): 16 ARTnaive and 26 ART-experienced (4 treated children had genotypes before ART, 2 of whom also had a post-ART genotype). Of the 16 without sequences, 9 were suppressed, 5 had missing genotype reports, and 2 were ART-naive with no genotype.
Thirty-five percent (14/40) of children with available genotypes were infected with non-B subtypes (Table 2) Phylogeny demonstrated 6 subtypes, consistent with REGA subtyping (Figure 1 ). Within individual subtypes, 4 clusters were observed, each with 2 individuals. All clusters had high bootstrap support and were epidemiologically confirmed: 1 subtype C cluster of 2 perinatally infected brothers (ID17/36), and 3 subtype B clusters-2 (ID1/ID2 and ID15/ID32) mother-child pairs (all clinic patients), and 1 male-to-female pair (ID7/ID8). The latter was a horizontal transmission cluster of a newly diagnosed teenage female, epidemiologically linked to her teenage perinatally infected male boyfriend, who was failing ART (Figure 1 ). Both had identical dual-class DR.
Virologic Failure
Of 44 ART-experienced children, 57% (25/44) were categorized as virologically failing (Table 1 and Of the 7 covariates tested, higher likelihood of failure was associated with poor treatment adherence as represented by history of missed clinic appointments (odds ratio [OR], 5.7; 95% confidence interval [CI], 1.0-32.1; P = .05) or medication doses (OR, 16.2; 95% CI, 2.1-124.7; P = .007), and showed a trend toward association with lack of HIV disclosure (OR, 23.3; 95% CI, .66-819; P = .08) ( Table 3) .
Compared to suppressed children, the ART-failing group was older at diagnosis, and had higher proportions of males, blacks, Hispanics, refugees, perinatal infections, biological-parent caretaker, prior non-HAART regimens, a drug holiday history, and more lifetime antiretroviral regimens, as well as lower median CD4 cell count and percentage at the start of ART and at the most recent appointment (Table 1 ). Formal statistical testing was not done for these covariates.
DR Among ART-Naive Children
Sixteen children had available pre-ART genotypes; median age at testing was 15 years (range, 0.3-19 years); 63% were female; 44% (7/16) were US-born, 25% (4/16) African-born, 13% (2/16) Caribbean-born, and 19% (3/16) unknown; 19% were refugees; and 63% (10/16) were horizontally infected (sexual contact), 25% (4/16) perinatally infected, and 13% (2/16) unknown. Only 1 of 4 perinatally-infected children (ID12, CRF02_AG) received zidovudine prophylaxis, and had no TDR. Two of the 16 children with pre-ART genotypes had sequences both before and after treatment initiation: ID9 (subtype A, unknown mode of transmission) and ID29 (CRF24_BG, horizontally infected); both with no TDR in the naive genotype; ID9 consequently developed nonnucleoside reverse transcriptase inhibitor (NNRTI) DR (V108I) while on treatment.
DRMs were seen in 25% (4/16) of children according to the IAS-USA list [26] , but only 6% (1/16) according to the WHO SDRM list [27] . Minor protease inhibitor (PI) mutations, considered polymorphisms in some non-B subtypes, differ between the mutation lists and were the reason for the discordance.
DR Among ART-Experienced Children
Sixty-six sequences from 26 ART-experienced children were available: 77% (20/26) from group 2, 27% (7/26) from group 3, and 27% (7/26) from group 4. Ninety-two percent (24/26; 95% CI, 75%-99%) of ART-experienced children had at least 1 cumulative DRM based on the IAS-USA list. Excluding minor PI mutations, 73% (19/26; 95% CI, 52%-88%) had DR; of these, 16% (3/19) had triple-class, 47% (9/19) dual-class, and 37% (7/19) single-class DR ( Compared to those without DR, children with DR were younger at diagnosis and perinatally infected, and had prior non-HAART regimens, a greater number of lifetime regimens, lower median CD4 cell counts and percentages at ART start and at the most recent appointment, and a decrease in CD4 cell counts on treatment (median change, −107 cells/mL; range, −781 to 663 cells/mL) ( Table 1) .
Of the 7 covariates tested, DR was observed more among those with caretaker change (OR, 2.41; 95% CI, .26-33.18; P = .64), history of missed doses (OR, 3.19; 95% CI, .04-281.5; P = .45), psychiatric diagnosis (OR, 2.68; 95% CI, .23-148.2; P = .63), and subtype B (OR, 1.59; 95% CI, .18-13.19; P = .66) ( Table 3) . History of nondisclosure appeared to be protective (OR, 0.16; 95% CI, .01-1.32; P = .07). None of the tests reached statistical significance with P < .05. 
DISCUSSION
We report treatment outcomes in all 56 children seen between 1991 and 2012 at the only pediatric HIV clinic in Rhode Island, and DR, subtype diversity, and molecular epidemiology in those with available sequences (71%). More than half (57%) of ARTexperienced children had virologic failure, 32% never suppressed, with higher likelihood of failure associated with lack of disclosure and treatment adherence. Genotypes demonstrated low (6%) TDR and high (73%) acquired DR, 63% dual or triple class. One epidemiologically confirmed transmission cluster was observed, with dual-class DR transmission. Although new US pediatric HIV infections are low, our comprehensive results highlight the need to intensely monitor HIVinfected pediatric populations as they mature to adulthood and the continued need to identify interventions to reduce treatment failure and DR development in these populations. We observed higher non-B subtype pediatric infections (35%) than previous US reports (range, 2.7%-17% [10, 11, 16] ). All children with non-B subtypes in our clinic were either born outside the United States or had parents of foreign origin, and 64% were refugees. Rhode Island is a common destination for refugees, immigrants, and other foreign-born individuals, specifically from West Africa [28] . US pediatric clinics in settings that provide services for refugees and immigrants should be aware of the possibility of higher subtype diversity. Moreover, 3 children with non-B subtypes were born in the United States, and 1 was horizontally infected. Awareness should therefore not be limited to foreignborn individuals. Although in our data, subtype was not associated with treatment failure or DR, possibly due to small sample size, the importance of awareness to subtype as part of clinical care remains to be determined [17, 29, 30] .
Seventy-three percent of treated children with available genotypes had major DRMs, 63% dual-or triple-class. This was seen particularly in children previously exposed to monotherapy or dual therapy. These results are consistent with US and European reports of multiclass DR in 30%-81% of children failing ART [14, 15, 31] . Children failing ART and those with DR were more likely to have been on a non-HAART regimen and on more lifetime regimens, and were exposed to twice as many drugs. This likely reflects the increased availability of pediatric formulations over time, such that older children who started ART earlier (especially pre-HAART) were more likely to be suboptimally suppressed, and therefore experienced more drug changes. These results emphasize the importance of supporting strict medication adherence and possibly of minimizing unnecessary regimen changes, although the latter was not formally tested here.
Assessment and reporting of DR is highly dependent on the mutation list used, as demonstrated here for both transmitted and acquired DR. The IAS-USA list [26] includes additional mutations not listed on the WHO SDRM list [27] , as well as minor PI mutations, which may be associated with ART but are also polymorphisms in non-B subtypes. Similar observations of mutation list discordance have been reported in subtype C-infected Indian children [32] . As HIV-1 diversity rises, these considerations are increasingly important in the United States to avoid erroneous conclusions and overestimation of DRM.
Only 1 child in our cohort had "true" transmitted DR, acquired by heterosexual contact. To our knowledge, this is the first report of a phylogenetic and epidemiologic transmission cluster in children. Such observations, more common in adults, including in Rhode Island [22] , raise concern for increased HIV and DR transmission as HIV-infected children come of age and commence sexual activity. Attention is needed to advance research on the impact of phylogeny and transmission networks reconstruction in these populations.
The comprehensive inclusion of 100% of clinic children since 1991 is a strength of this study, allowing for several observations. Treatment adherence, as represented by history of missed appointments and reported missed medication doses, was significantly associated with virologic failure, strengthening previous reports [33, 34] , but not with DR. The lack of association of these factors with DR may be due to the small sample size, but may also represent lack of, as opposed to reduced, treatment adherence. Missing ART results in absence of selection pressure and lack of selection for drug-resistant strains. Therefore, completely nonadherent children might have high VLs with no detectable resistance [35] . More research on the impact of nonadherence on DR in children is warranted.
Fewer virologically suppressed children had their biological parents as primary caregivers and more were adopted. Having a primary caregiver who is not the biological parent has been associated with better adherence [36] . The parents of a perinatally infected child might themselves be infected and need to address their own health or deal with guilt of transmission of infection to the child, which may impact their ability to adequately care for their HIV-infected child [37] . Although these findings were not formally tested here, they may be relevant for consideration by clinicians.
Examination of the association of disclosure with virologic failure and DR showed mixed results. Lack of disclosure demonstrated a trend toward association with virologic failure. An age-appropriate child who is unaware of his or her infection might not understand the importance of strict adherence. Conversely, lack of disclosure was lower in those with DR. One possible explanation for this observation could be that by the time a child develops DR, he or she might have learned of the HIV diagnosis as part of the clinical team's effort to improve adherence. Literature reports of the effect of disclosure on adherence are also mixed [38, 39] . The American Academy of Pediatrics recommends disclosure to school-aged children and that all infected adolescents know their HIV status [40] . Our results support this recommendation, but highlight the complexity of this issue and the need for its further refinement. The table is sorted according to total number of mutations, in descending order. Mutation nomenclature: amino acid position (number) followed by amino acid substitution conferring resistance.
Abbreviations: CRF, circulating recombinant form; DRM, drug resistance mutations; NNRTI, nonnucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor; PI, protease inhibitor; U, unknown.
Amino acid abbreviations: #, insertion; A, alanine; C, cysteine; D, aspartate; Dx, Dosage; E, glutamate; F, phenylalanine; G, glycine; H, histidine; I, isoleucine; ID, identification; L, leucine; M, methionine; N, asparagine; P, proline; Q, glutamine; R, arginine; S, serine; V, valine; W, tryptophan; Y, tyrosine. a Age at diagnosis in years (y), months (m), or days (d).
b Age at first genotype (in years).
c Time (months) from first genotype to the genotype when mutations were accumulated, or to the most recent genotype for those with no accumulation.
d Mutations not present in the first available genotype.
e Only 1 sequence available.
f No mutation accumulation.
Our study had several limitations. First, it was retrospective with some missing covariate data. Second, adherence was measured indirectly through chart and verbal reports, which may not be indicative of true adherence [36] . Third, most ARTnaive children with genotypes were not newly infected, possibly resulting in underestimated TDR due to viral reversion to wildtype with no ART pressure [35] . Last, the small number of children limited statistical analyses of correlates of failure and DR to a few variables. This is a major limitation that is a result of the good outcome of low perinatal infections in the United States and Rhode Island.
In conclusion, this study is informative for pediatricians caring for HIV-infected children who are at risk of treatment failure and DR development. This risk is augmented as children enter adulthood and initiate sexual activity. Although new US infections are low, pediatricians need to continue to be vigilant and provide psychosocial support to ensure excellent adherence to ART. Strategic selection of regimens should maximize effectiveness while optimizing adherence, to reduce the potential for DR development.
Notes
